Daniela Moïsi

3.5k citations

68 papers · 2.6k indexed · 1 hit paper · h-index 27

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Infectious Diseases 59
- HIV/AIDS drug development and treatment 50
- HIV/AIDS Research and Interventions 34
- SARS-CoV-2 and COVID-19 Research 3
Virology 56
- HIV Research and Treatment 56

Co-authors: Mark A. Wainberg (49 shared papers)Bluma Brenner (45 shared papers)Maureen Oliveira (35 shared papers)Michel Roger (9 shared papers)Jean‐Pierre Routy (8 shared papers)Michel Ntemgwa (9 shared papers)Mervi Detorio (8 shared papers)Hugues Charest (6 shared papers)
Journals: Antimicrobial Agents and Chemotherapy (16 papers)AIDS (11 papers)Journal of Antimicrobial Chemotherapy (5 papers)Open Forum Infectious Diseases (4 papers)PLoS ONE (4 papers)
Partner nations: Canada United States Uganda

In The Last Decade

Daniela Moïsi

64 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

High Rates of Forward Transmission Events after Acute/Early HIV‐1 Infection 2007 · 501 citations

Peers

Countries citing papers authored by Daniela Moïsi

Since Specialization

Citations

This map shows the geographic impact of Daniela Moïsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Moïsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Moïsi more than expected).

Fields of papers citing papers by Daniela Moïsi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Moïsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Moïsi. The network helps show where Daniela Moïsi may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniela Moïsi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniela Moïsi Line = papers co-authored together Daniela Moïsi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	High Rates of Forward Transmission Events after Acute/Early HIV‐1 Infection The Journal of Infectious Diseases ·Bluma Brenner, Michel Roger, Jean‐Pierre Routy, Daniela Moïsi, Michel Ntemgwa, Claudine Matte, Jean‐Guy Baril, Réjean Thomas, Danielle Rouleau, Julie Bruneau, Roger LeBlanc, Mario Legault, Cécile Tremblay, Hugues Charest, Mark A. Wainberg, (unknown) Hit paper breakdown →	2007	501
2	A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors AIDS ·Bluma Brenner, Dan Turner, Maureen Oliveira, Daniela Moïsi, Mervi Detorio, Mauricio Carobene, Richard Marlink, Jonathan Schapiro, Michel Roger, Mark A. Wainberg	2003	242
3	Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection Journal of Virology ·Bluma Brenner, Jean‐Pierre Routy, Marco Petrella, Daniela Moïsi, Maureen Oliveira, Mervi Detorio, Bonnie Spira, Vidal Essabag, Brian Conway, Richard Lalonde, Rafick‐Pierre Sékaly, Mark A. Wainberg	2002	177
4	HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture AIDS ·Bluma Brenner, Maureen Oliveira, Florence Doualla‐Bell, Daniela Moïsi, Michel Ntemgwa, Fernando Frankel, Max Essex, Mark A. Wainberg	2006	174
5	Transmission networks of drug resistance acquired in primary/early stage HIV infection AIDS ·Bluma Brenner, Michel Roger, Daniela Moïsi, Maureen Oliveira, Isabelle Hardy, Reuven Turgel, Hugues Charest, Jean‐Pierre Routy, Mark A. Wainberg	2008	103
6	Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT Antimicrobial Agents and Chemotherapy ·Hugues Loemba, Bluma Brenner, Michael A. Parniak, Shlomo Maayan, Bonnie Spira, Daniela Moïsi, Maureen Oliveira, Mervi Detorio, Mark A. Wainberg	2002	102
7	Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection AIDS ·Bluma Brenner, Jean‐Pierre Routy, Yudong Quan, Daniela Moïsi, Maureen Oliveira, Dan Turner, Mark A. Wainberg	2004	96
8	Transmission Clustering Drives the Onward Spread of the HIV Epidemic Among Men Who Have Sex With Men in Quebec The Journal of Infectious Diseases ·Bluma Brenner, Michel Roger, David A. Stephens, Daniela Moïsi, Isabelle Hardy, Jonathan Weinberg, Reuven Turgel, Hugues Charest, James S. Koopman, Mark A. Wainberg, (unknown)	2011	90
9	Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1 Journal of Virology ·Dimitrios Coutsinos, Cédric Invernizzi, Hongtao Xu, Daniela Moïsi, Maureen Oliveira, Bluma Brenner, Mark A. Wainberg	2008	71
10	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy Open Forum Infectious Diseases ·Meagan P. O’Brien, Peter W. Hunt, Douglas Kitch, Karin L. Klingman, James H. Stein, Nicholas Funderburg, Jeffrey S. Berger, Pablo Tebas, Brian Clagett, Daniela Moïsi, Netanya S. Utay, Fran Aweeka, Judith A. Aberg	2017	62
11	Subtype diversity associated with the development of HIV‐1 resistance to integrase inhibitors Journal of Medical Virology ·Bluma Brenner, Matthew Lowe, Daniela Moïsi, Isabelle Hardy, Simon Gagnon, Hugues Charest, J.-G. Baril, Mark A. Wainberg, Michel Roger	2011	59
12	Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors Antimicrobial Agents and Chemotherapy ·Michel Ntemgwa, Bluma Brenner, Maureen Oliveira, Daniela Moïsi, Mark A. Wainberg	2006	53
13	Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors AIDS ·Maureen Oliveira, Thibault Mésplède, Peter K. Quashie, Daniela Moïsi, Mark A. Wainberg	2014	48
14	Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes Antimicrobial Agents and Chemotherapy ·Eugene L. Asahchop, Maureen Oliveira, Mark A. Wainberg, Bluma Brenner, Daniela Moïsi, Thomas d’Aquin Toni, Cécile Tremblay	2010	48
15	Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection JAIDS Journal of Acquired Immune Deficiency Syndromes ·Dan Turner, Bluma Brenner, Jean‐Pierre Routy, Daniela Moïsi, Zeev Rosberger, Michel Roger, Mark A. Wainberg	2004	46
16	Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV‐1 Subtype C The Journal of Infectious Diseases ·Cédric Invernizzi, Dimitrios Coutsinos, Maureen Oliveira, Daniela Moïsi, Bluma Brenner, Mark A. Wainberg	2009	46
17	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus Clinical Infectious Diseases ·Vincent C. Marconi, Carlee Moser, Christina Gavegnano, Steven G. Deeks, Michael M. Lederman, Edgar T. Overton, Athe Tsibris, Peter W. Hunt, Amy Kantor, Rafick‐Pierre Sékaly, Randall Tressler, Charles Flexner, Selwyn J. Hurwitz, Daniela Moïsi, Brian Clagett, William R. Hardin, Carlos del Rı́o, Raymond F. Schinazi, Jeffrey Lennox	2021	43
18	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy–mediated Viral Suppression Clinical Infectious Diseases ·Martin Hoenigl, Carlee Moser, Nicholas Funderburg, Ronald J. Bosch, Amy Kantor, Yonglong Zhang, Jesper Eugen‐Olsen, Malcolm Finkelman, Jochen Reiser, Alan Landay, Daniela Moïsi, Michael M. Lederman, Sara Gianella	2018	41
19	In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine Antimicrobial Agents and Chemotherapy ·Susan M. Schader, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Daniela Moïsi, Susan P. Colby-Germinario, Mark A. Wainberg	2011	38
20	A Template-Dependent Dislocation Mechanism Potentiates K65R Reverse Transcriptase Mutation Development in Subtype C Variants of HIV-1 PLoS ONE ·Dimitrios Coutsinos, Cédric Invernizzi, Daniela Moïsi, Maureen Oliveira, Jorge Martínez-Cajas, Bluma Brenner, Mark A. Wainberg	2011	36

About Daniela Moïsi

Daniela Moïsi is a scholar working on Infectious Diseases, Virology, Epidemiology, Molecular Biology and Emergency Medicine, having authored 68 papers that have together received 2.6k indexed citations. Recurring topics across this work include HIV Research and Treatment (56 papers), HIV/AIDS drug development and treatment (50 papers), HIV/AIDS Research and Interventions (34 papers), Pneumocystis jirovecii pneumonia detection and treatment (12 papers), Biochemical and Molecular Research (9 papers), HIV-related health complications and treatments (7 papers), Hepatitis C virus research (3 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). The work is most often cited by research in Virology (2.2k citations), Infectious Diseases (2.4k citations), Epidemiology (654 citations), Emergency Medicine (154 citations) and Hepatology (102 citations). Daniela Moïsi has collaborated with scholars based in Canada, United States and Uganda. Frequent co-authors include Mark A. Wainberg, Bluma Brenner, Maureen Oliveira, Michel Roger, Jean‐Pierre Routy, Michel Ntemgwa, Mervi Detorio, Hugues Charest, Dan Turner and Cécile Tremblay. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, AIDS, Journal of Antimicrobial Chemotherapy, Open Forum Infectious Diseases and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact